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 Executive Summary 
 
Bangladesh is a densely populated country situated at South- East Asia. Although the 
geographical area of the country is not that big, but the country is huge (8th in the world) in 
terms of the population (close to 160 million). Considering diabetes under the health sector, 
5.9 million people have diabetes today and that would rise to 16.6 million by 2030. Per capita 
health expenditure is 152 DKK which is 3.7% of the GDP. To combat the disease, groups and 
institutions are serving through different public and private hospitals. Besides, Diabetes 
Association of Bangladesh (BADAS) is playing a crucial role. Everyday more than 12,000 
patients are served by them through different DAB centres, National Health Care Network 
(NHN) centres, Health Care Development Project (HCDP) centres around the country. This 
altogether constitutes a complete and integrated diabetes care management system in the 
country. 
 
Having this world class diabetes care infrastructure in place, only 25% patients have access to 
treatment and within that 25% also the treatment outcome needs further improvement. There 
is an urgent need for change, which can be brought in through the Changing Diabetes® 
Barometer (CDB) and Novo Care Project.  
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 Introduction 
The pharmaceutical industry in Bangladesh is one of the most developed and technology 
intensive sector which has an immense contribution to the national economy. Bangladesh 
Pharmaceutical Industry is now heading towards self-sufficiency in meeting the local demand. 
The industry is the second highest contributor to the national exchequer after garments. The 
pharmaceutical industry is worth around 1,500 million USD in Bangladesh, which has more 
than 250 companies of which 200 run their own manufacturing facilities including six out of 
the ten multinationals. Nearly 85 % of the domestic requirement is met by the top 20 
companies and almost 95 % of the requirements are met by locally manufactured medicines. 
Diabetes Care in the country is highly organized courtesy of Diabetic Association of 
Bangladesh (DAB). It is a non-profit voluntary socio-medical service organization, the largest 
healthcare provider among the private and non-government organizations. Diabetes and Pre-
diabetes prevalence in Bangladesh is around 19 million. Diabetes Association of Bangladesh 
(DAB) has piloted one of the largest health program in the world following Public-Private and 
Private-Private partnership model. DAB has nearly 25% of diabetic population enrolled in 
their network of nearly 145 healthcare facilities and are currently treating 14,000 out-patients. 
BIRDEM hospital treats over 3500 patient’s everyday making it the world’s largest diabetes 
care centre. 
The top 10 pharmaceutical companies in Bangladesh are Square, Incepta Pharma, Beximco, 
Opsonon, Renta, Eskayef, Aristpharma, ACI, Acme, and Healthcare. Top five multinational 
pharmaceutical companies in Bangladesh are Sanofi Bangladesh, Novo Nordisk, 
GlaxoSmithKline, Novartis and Sandoz. 
Novo Nordisk is a global healthcare company with 90 years of innovation and leadership in 
diabetes care. The company also has leading positions within Hemophilia care, Growth 
hormone therapy and Hormone replacement therapy. Headquartered in Denmark, Novo 
Nordisk employs approximately 40,300 employees in 75 countries, and markets its products 
in more than 180 countries. A world leader in Diabetes since 1923, Novo Nordisk has 
production facilities present in 7 countries. 
Novo Nordisk has been commercially active in Bangladesh for more than half a century, 
selling insulin in the country since 1957. In 1999 liaison office of Novo Nordisk A/S was set 
up in Dhaka in2004. Till March 2006, the liaison office ran its operation through one sole 
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 distributor International Agencies, Bangladesh and it was responsible for registration, sales 
activities, storage as well as distribution.In April 2006, Transcom Distribution Company Ltd 
(TDCL) was made the sole distributor and was responsible for registration, sales and 
distribution of the products.  
In January 24th 2007, Novo Nordisk Pharma Pvt Ltd was set up with its headquarters in 
Dhaka. At present, the company has about 60 per cent share in Bangladesh insulin market. In 
Bangladesh, Novo Nordisk has been actively supporting healthcare system strengthening 
through physician education, infrastructure development and affordability improvements. The 
value to the Bangladeshi society is reflected in higher rates of diagnosis, treatment initiation 
and improved overall quality of diabetes care in the country. For more than 50 years, Novo 
Nordisk has been the leader in diabetes care in Bangladesh and has a historical long 
partnership with the Diabetic Association of Bangladesh (DAB) and committed to fight 
against the disease together. In Bangladesh, Novo Nordisk  broaden HCP knowledge about 
diabetes through the Distance Learning Programme (DLP); make medications affordable 
through LDC pricing policies; it ensure that treatment for children is accessible and affordable 
through the Changing Diabetes in Children Programme (CDiC); and  increased the 
availability of high-quality medication by improving the distribution chain.  
The vast majority of Novo Nordisk insulin’s are imported from its plants in Denmark and 
France supported by its strong and wide supply chain network globally. Only a small 
proportion of its Human Insulins are produced locally upon a partnership agreement with 
Eskayef Bangladesh ltd in a high-tech insulin manufacturing plant since December 2012. 
Eskayef Bangladesh Ltd is one of the leading 
health care solution providers in Bangladesh 
with its Cephalosporin plant been accredited 
by MHRA, UK& TG, Australia.    
Transcom Distribution Company Limited 
(TDCL) is the importer and distributor of 
Novo Nordisk products since 2006 and is the 
leading distribution company in Bangladesh 
with a strong network with over 28 
distribution centers across the country. They 
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 supply products to over 115,000 retailers and wholesalers daily throughout the country. 
 
 
Bringing difference through 
Changing Diabetes® Barometer 
In Bangladesh 
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Bringing difference through Changing Diabetes Barometer (CDB) 
 
Bangladesh is a densely populated country situated at the South East Asia region. Although 
the geographical area of the country is not that big, but in the terms of population, the country 
is 8th largest in the world with a population close to 169 million. Considering diabetes under 
the health sector, 7.1 million people have diabetes today which is estimated to rise to 16.6 
million by 2030. The per capita health expenditure in Bangladesh is one of the lowest in the 
world with 5.5 % of the GDP. In order to combat the disease, people are serving through 
different public and private hospitals. In the fight against Diabetes, the Diabetes Association 
of Bangladesh (BADAS) is playing an extremely critical role in the country. Everyday around 
the country more than 12,000 patients are served by them through different DAB centers, 
National Health Network (NHN) centers and Health Care Development Project (HCDP) 
centers. This altogether constitutes a complete and integrated diabetes care management 
system in the country. 
PURPOSE OF CDB 
In spite of this, more than 25% of diabetes patients are deprived of getting proper treatment in 
the country. Additionally half of the total diabetes patients are still undiagnosed. All these 
lead to ultimately cost 129,313 lives in 2015. In the health sector, diabetes is running like a 
race with no holds bar. So there is an urgent need for change, which can be brought in through 
the Changing Diabetes® Barometer (CDB) project. 
 
Under this project, the prime target is to provide diabetes care management to more patients 
through providing more support to train-up HCPs, establishing more improvised and 
automated registry system in the centres and ultimately to ensure the best treatment to more 
patients. At present diabetes management system in Bangladesh is not fully equipped with an 
automated registry system. So there always lacks an opportunity to track down the treatment 
pattern and the number of patients. By incorporating the full-fledged and automated registry 
support it is possible to measure the quality of treatment pattern and patient history. 
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 STRATEGIC REASONS 
Novo Nordisk Bangladesh has always been working for the betterment of the patients with 
diabetes. Through participating and initiating different programs, strategies and campaigns it 
has tried to help BADAS to develop a comprehensive structure of the diabetes management 
system. 
 
BADAS has taken the target to reach at least 50% of the patients by 2020. It can only be 
possible when people will be more aware to screen and diagnose their diabetes condition. In 
collaboration with BADAS, Novo Nordisk Bangladesh is working together on that objective. 
Under this strategy- 
 
o More awareness programs are initiated and conducted throughout the country 
 
o Free of cost blood glucose screening and HbA1c screening (for patient with 
high BG) are provided 
 
o Automated patient registry system is being established in the centres to retain 
complete patient data 
 
o In collaboration with diabetes management centres, insulin help desk corner is 
incorporated to provide support to the new insulin users 
 
These initiatives are providing from three perspectives- Patients, Doctors and Diabetes 
management centers. 
 
o For Patients: 
 
 Run diabetes awareness program in selected geography of the country 
to raise consciousness of the patients 
 
 Make patient aware about diabetes, its complications and importance of 
good glycaemia control 
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  Support HCPs training on diabetes management, life-style modification 
and insulin intake 
 
 Free blood glucose screening camp & HbA1c screening for patients 
with high BG  
 
o For Doctors: 
 
 Training of HCPs on quarterly & monthly basis to provide enhanced 
update on better glycaemia control 
 
 Make the HCPs aware that early insulin intake is vital for enhanced 
diabetes management 
 
o For diabetes management centres: 
 
 Provide support to create computer based patient registry database.  
 
 Insulin Help Desk Corner  helps to counsel patients on any queries 
 
• Before Changing Diabetes Barometer project, no patient registry system was present 
in the centres. Diabetes centres only provided a history book to the patients which 
patients used to bring with them during each visit. So it was difficult for both the 
doctors and centres to retain any documented patient data. It was really very 
challenging for the doctors to monitor the progress of their patient. The automated 
registry system was able to retain all the patient data from the initiation to the patient 
treatment. As a result, doctors can track down the information of all of his/her patients 
with their progress pattern and can change the treatment process as per requirement. 
The doctors can also find out how many patient he has treated and which treatment 
protocol is better for good glycaemia control. 
 
The centres will also be benefitted from this registry system as it will have a complete 
patient database. Depending on that, the centres can take necessary measures for 
infrastructural development and necessary improvement.  
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From all these measures, the patient will ultimately receive the best treatment. The 
patient will not be required to carry the history book during every visit to the doctor. 
 
To conclude, the registry system is a landmark for the development of diabetes 
treatment. Through the triple way drive, the automated registry system will eventually 
bring in the change in the diabetes management of Bangladesh. 
 
CHALLENGES INVOLVED 
 
Novo Nordisk started to work on this project from October 2014. The development works 
continued up to January 2015. In this time period, it was launched as a pilot project in one of 
the selected centre (Mirpur NHN). On initial phase, Novo Nordisk selected 20 centres around 
the country. Finally, it was launched in full phase on 7th February 2015. Till now the project 
has been initiated in over 30 centres across the country. There are lots of activities involved in 
the project, where different kinds of logistics support are required to provide in the centres 
including the automated registry system. 
 
Project Operation: 
 
 
 
 
 
Initiation of insulin & titration 
by investigator Data analysis Share the outcome 
and publication 
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 IMPACT OF CDB 
Income levels of Bangladeshis are generally very low. They usually do not go for 
comparatively high cost diagnosis experiments like- HbA1c. So in most of the cases, doctors 
cannot track down actual blood glucose level of their patients. Under the CDB project, 
patients are getting free of cost HbA1c measurement opportunity. So it ultimately helps the 
doctor to choose right treatment option and the patient will also get more accurate treatment 
regimen for better glycogenic control. Through CDB monitoring the number of HbA1C done 
previously have become easy after incorporating this free test facility. It will also help to track 
down the prescription habit of the doctors, whether they prefer human insulin or modern 
insulin for their patients and to how much extent they prefer to switch from human to modern 
insulin or choose to provide modern insulin in early initiation. 
 
Due to this project the number of HbA1c test has risen significantly in the centers. Both 
doctors and patients are getting more accurate information on glycogenic control. Number of 
modern insulin users in early phase of treatment has increased and it ultimately puts a positive 
impact on the number of total insulin users. 
 
At present Novo Nordisk intends to launch the project further in other regions of the country, 
which will be eventually expanded to 130 centers. This project will ultimately contribute to 
the health and socio-economic condition of the country as well. Firstly, more people will 
come under the umbrella of diabetes diagnosis through free campaigns. It will ultimately help 
them to get better treatment. Moreover, there will be no extra cost burden on the patients for 
their diagnosis. Hence free blood glucose screening and HbA1c campaign will help the 
country in terms of both socio-economic and health perspective.  
 
This program is under the category C of GCN awards. In this category Changing Diabetes® is 
a common phenomenon. But this program intends to change diabetes and also the 
development of the country as a whole. So this is a program that has the ability to make a 
positive impact on a financial, social and environmental scale. This distinctive program can 
be adapted by other GCN members because it will be helpful for their people also. 
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 Project Organogram 
 
 
 
The project steering committee of CDB is comprised of the Project Leader, Mr Sukanta Das 
(SKDS), Project Coordinator, Ms Nazmun Peya, Sub Project Partner Mohammed Saiful Islam 
(MXDI) Sub Project Partner Pharmacovigilance Ms Fahima Hassan (FIAL), Sub Project 
Partner Operations Mohammed Zubair Matin (MMZB), Sub Project Partner Legal Ms 
Tasnuva Shelly (TSY), Sub Project Partner Islam Mohammed Saiful (MSFU), Sub Project 
Partner Market Access Ms Farjana Ehsan (FJEH) and Mr Gazi Tawhid Ahmed (GTWA).  
Recruitment and Training Partner includes Head of Human Resources Ms Noomaya Azad and 
HR Executive Mr Hamza Hemal.  
 
An integrated approach that ensures highest standard service 
 
Novo Nordisk Bangladesh has always been working for the betterment of the patients with 
Diabetic association. Through participating and initiating different programs, strategies and 
campaigns it has tried to help BADAS to develop a comprehensive structure of the diabetes 
management system. It is well established that, better HbA1c control is associated with long 
term health benefits. Every 1% drop in HbA1c results in- 
 
• 43% reduction in lower extremity amputation or fatal peripheral vascular disease 
• 37% less chance of micro vascular disease 
• 19% reduction in cataract 
• 16% decrease in heart failure 
• 14% lessening of myocardial infarction 
Project steering 
committee (CDB)
Sub Project Lead:
Project 
Coordinator
Sub Project Partner 
(PV/ 
Quality/Operations):
FIAL/MXDI/MMZB
Sub Project 
Partner (FLIT):
TSY/MSFU
Sub Project 
Partner (MAPA):
FJEH/GTWA
Recruitment and 
Training:
NYJ/MZHM
Project Lead:
SKDS
10 
 
 • 12% lower chance of stroke 
 
So, control of HbA1c at optimal level is so important for overall wellness of the patients. 
 
Under Changing Diabetes® Barometer in Bangladesh, the prime target is to provide diabetes 
care management to more patients through Diabetic Association by providing more support to 
train-up HCPs, establishing more improvised and automated registry system in the centres 
and ultimately to ensure the best treatment to more patients. 
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 Contribution to the society: 
 
CDB is a kind of project, through which more people will come under the umbrella of 
diabetes diagnosis through free campaigns. It will ultimately help them to get better treatment. 
Moreover, there will be no extra cost burden on the patients for their diagnosis. Specially, 
HbA1c is a costly test, which is not always feasible for patients to financially partake. That is 
why free HbA1c blood glucose screening will help the country in terms of both socio-
economic and health perspective 
 
From all these measures, the patient will ultimately get the best treatment for himself. The 
patient will not be even required to carry the history book during every visit to his/her doctor. 
In a phrase, the registry system will be a landmark for the development of diabetes treatment. 
Through the triple way drive, the automated registry system will eventually bring in change in 
the diabetes management of Bangladesh. 
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 Project design: 
 
 
 
 
Pro Prof . Nazmun Nahar  ADVISOR 
Co- Investigator 
Coordinator (OPD) Dr. Zakera Yesmat  
Investigator Total 10 (Approx) 
Health Educator 1 person 
Prof. Zafar A Latif 
BIRDEM Academy 
Prof. F Pathan 
Endocrine Department  Dr. SM Ashrafuzzaman 
Principle 
Investigator 
Data Entry 2 persons 
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 Changing Diabetes Barometer Project Contents 
 
(Financial support is borne by Novo Nordisk Pharma (Pvt) Ltd) 
 
No. Item name Description 
1 Software Patient enrolment software and auto sms service. Software will be designed with the guideline of academy 
2 Hardware Desktop PC (core i-5) full set with printer, modem with 2 GB internet service  
3 HbA1c HbA1c cost to the centre 
4 Project Cost Maintenance cost for project 
 
 
Deliverables: 
 
No.  Deliverable by  BIRDEM  
Deliverable by  
Novo Nordisk 
1 Project approval Project Support in verbal and written form 
2   Financial support 
3 Content of software and ownership Development of software 
4   User acceptance testing confirmation 
5 All type of content for development of physicians   
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NovoCare 
 (For high valued insulin users in Bangladesh) 
NovoCare is an exclusive Patient Support Program, an initiative of Novo Nordisk Bangladesh 
and powered by SSL for high end insulin users. Typically the center acts as the first contact 
and principal point of continuing care for patients. For the first time, doctors directly speak 
and provide value added services to the patients& monitor them at regular basis. It can be 
proceeding in 2 phases: 
 
 Phase 1: 
 Anytime access to doctors and doctor-call-back service; (Patients can 
directly engage with the doctors anytime while dedicated doctors are 
available who serves the patients according to their needs) 
 Electronic personal medical record; (Treatment related all the data will 
be digitally recorded ) 
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  Patient’s access to online personal health record through the Internet; 
(A web site will be developed and the patients can be able to show their 
treatment profile & regular treatment update through internet by 
accessing that web site )  
 Mobile phone applications will be installed for daily blood glucose, 
blood pressure, weight and HbA1c record keeping; ( Initially a patient 
can monitor or update their profile through mobile viewable website) 
 Phase 2: 
 Online access to patient’s record for Medical Consultants, 
Endocrinologists and Dialectologists only for their respective patients 
 Graphical representation of patients progress in concert with usage of 
insulin; 
 Reminder to take medications, purchase drugs, diabetes supplies, etc. 
Objectives for insulin user Support Program: 
• Establish ease-of-use and convenience around insulin Users (initiation and use) 
amongst HCPs and patients. 
• Provide a value-added patient program to differentiate and reinforce 
commitment to Diabetes.   
• Give patients an opportunity to receive additional training and support in 
administration of the modern device. 
• To increase the patient compliance and adherence to therapy and thereby 
reducing long term complication 
• Support patients with: 
• Education: Arrange monthly patient awareness program to educate the 
patients about their disease, prevalence, remedies & treatment. 
• Reminders: Always follow up the patients concerning their treatment & 
diagnosis. 
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 • Injection + Medication Alerts  
• Intensive support during first 2 weeks to prevent drop-outs: When a 
new patient is enlisted, in the first two weeks the team monitors the 
patient in a bi weekly basis to prevent drop out cases. 
• Doctor Call Back: In a regular basis, the responsible doctor monitors 
their patient over phone. 
Target Audiences: 
Primary care Physician & their administrative assistants, Endocrinologist, General 
practitioner and most importantly insulin users are the targeted audience. 
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 NovoCare Process:  
NovoCare was launched on 20th April, 2015 
• Three processes of patient enrollment: 
• Online: Medical call center staff  does the  follow-up data collection over 
phone 
• Via Physician office using online or paper form 
• Via calling the hotline number  
The patient registration form will include acopy of patient’s prescription 
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The Role of the Health Care Professionals in Novo Care: 
 
1. Inform patients about the insulin user Support Program including Executive 
care program 
2. Enroll patient by completing enrolment form and fax in or by providing 
patient’s contact number to NovoCare  
3. Hand out patient brochure with attached device guide together with 
prescription 
4. To extend follow-up support to medical call center doctor via phone, when 
necessary 
 
Project Organogram
 
The project steering committee of Novo Care is comprised of Project Leader, Mr Sukanta Das 
(SKDS), Sub Project Owner Ms Quamsia Sultana (QSUL), Sub Project Lead Ms Nazmun 
Peya, Sub Project Partner Mohammed Saiful Islam (MXDI), Sub Project Partner 
PharmacovigilanceMs Fahima Hassan (FIAL), Sub Project Partner Operations Mohammed 
Zubair Matin (MMZB), Sub Project Partner Legal Ms Tasnuva Shelly (TSY), Sub Project 
Partner Islam Mohammed Saiful (MSFU), Sub Project Partner Market Access Ms Farjana 
Ehsan (FJEH) and Mr Gazi Tawhid Ahmed (GTWA).  Recruitment and Training Partner 
includes Head of Human Resources Ms Noomaya Azad and HR Executive Mr Hamza Hemal. 
Project steering 
committee 
(NovoCare)
Sub Project 
Owner:
QSUL
Sub Project 
Lead:
NovoCare PM
Sub Project Partner (PV 
/Quality/Operations):
MXDI/ FIAL/MMZB
Sub Project 
Partner (FLIT):
TSY/MSFU
Sub Project 
Partner (MAPA):
FJEH/GTWA
Recruitment and 
Training:
NYJ/MZHM
Project Lead:
SKDS
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My Job Description 
 
 
Responsible to organise, arrange and host IONextEight Workshops, Meetings with internal 
and external stakeholders. 
 
Plan, organise and arrange necessary refresher training and logistic support to all relevant 
concerns in the projects 
 
Communicate and coordinate to engage multi party stakeholders in the projects 
 
Management and Documentation of necessary logistics and materials to ensure compliance   
 
Address project issues & challenges and develop problem solving skills 
 
To become enlightened about the industry, market and commercial effectiveness, while 
developing understanding to analyse and interpret data 
 
Understand marketing theories, communication and business ethics 
 
Generate report and interpret data from Changing Diabetes Barometer and Novo Care 
Projects 
 
Track, monitor and update activity progress in the Projects 
 
Plan and develop the IONextEight Project Newsletter 
 
Ensure all necessary compliance in the projects 
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 CONCLUSION 
 
Novo Nordisk is a global healthcare company with 89 years of innovation and leadership in 
diabetes care. The company also has leading positions within hemophilia care, growth 
hormone therapy and hormone replacement therapy. Novo Nordisk strives to conduct its 
activities in a financially, environmentally and socially responsible way. The strategic 
commitment to corporate sustainability has brought the company onto the centre stage as a 
leading player in today’s business environment; recognized for its integrated reporting, 
stakeholder engagement and consistently high sustainability performance. Through the 
Changing Diabetes Barometer and NovoCare project, Novo Nordisk BD pharma believes it 
can provide a positive contribution to the diabetes population of Bangladesh by investing in 
infrastructures and resources that would aid physicians and health care professionals to track 
its patient’s condition make informed prescriptions backed by good quality data. 
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 Recommendation & Way Forward: 
 
Changing Diabetes Barometer (CDB) should eventually spread and incorporate all the 
Diabetic Association of Bangladesh or DAB centres, clinics and hospitals to serve the 
unsaved diabetic population.  
 
The DAB centres and institutions should produce academic and medical publications with the 
data generated by CDB and Novo Care so that it brings about a guideline to enhance diabetes 
management. 
 
More communication materials and messages should be developed to make the health care 
professionals and patients more aware of the value added services provided by Novo Care. 
 
Novo Nordisk should strategically engage BIRDEM academy in the CDB and Novo Care 
project so that BIRDEM can utilize the data to publish papers on better treatment adherence.   
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